BRPI0210707B8 - composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação - Google Patents

composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação

Info

Publication number
BRPI0210707B8
BRPI0210707B8 BRPI0210707A BR0210707A BRPI0210707B8 BR PI0210707 B8 BRPI0210707 B8 BR PI0210707B8 BR PI0210707 A BRPI0210707 A BR PI0210707A BR 0210707 A BR0210707 A BR 0210707A BR PI0210707 B8 BRPI0210707 B8 BR PI0210707B8
Authority
BR
Brazil
Prior art keywords
nose
eye
inflammatory disorders
topical administration
allergic
Prior art date
Application number
BRPI0210707A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0210707A (pt
BRPI0210707B1 (pt
Inventor
J Castillo Ernesto
G Bhagat Haresh
Zhang Huixiang
Paul Bullock Joseph
N Singh Onkar
C Dixit Suresh
Wehsin Han Wesley
Original Assignee
Alcon Pharmaceuticals Ltd
Alcon Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0210707(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Pharmaceuticals Ltd, Alcon Inc, Novartis Ag filed Critical Alcon Pharmaceuticals Ltd
Publication of BR0210707A publication Critical patent/BR0210707A/pt
Publication of BRPI0210707B1 publication Critical patent/BRPI0210707B1/pt
Publication of BRPI0210707B8 publication Critical patent/BRPI0210707B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0210707A 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação BRPI0210707B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30131501P 2001-06-27 2001-06-27
PCT/US2002/019417 WO2003002093A1 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Publications (3)

Publication Number Publication Date
BR0210707A BR0210707A (pt) 2004-07-20
BRPI0210707B1 BRPI0210707B1 (pt) 2015-08-04
BRPI0210707B8 true BRPI0210707B8 (pt) 2021-05-25

Family

ID=23162841

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210707A BRPI0210707B8 (pt) 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação

Country Status (20)

Country Link
US (2) US6995186B2 (enExample)
EP (1) EP1399127B1 (enExample)
JP (5) JP4827374B2 (enExample)
KR (1) KR100884711B1 (enExample)
CN (1) CN1211125C (enExample)
AR (1) AR034619A1 (enExample)
AT (1) ATE295149T1 (enExample)
AU (1) AU2002310461B2 (enExample)
BR (1) BRPI0210707B8 (enExample)
CA (1) CA2447924C (enExample)
DE (1) DE60204142T2 (enExample)
DK (1) DK1399127T3 (enExample)
ES (1) ES2238574T3 (enExample)
GC (1) GC0000397A (enExample)
MX (1) MXPA03011947A (enExample)
PL (1) PL205565B1 (enExample)
PT (1) PT1399127E (enExample)
TW (1) TWI231759B (enExample)
WO (1) WO2003002093A1 (enExample)
ZA (1) ZA200308771B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
KR101252863B1 (ko) * 2004-04-08 2013-04-09 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
US20070225356A1 (en) * 2004-04-21 2007-09-27 Kyowa Hakko Kogo Co., Ltd Preventive and/or Therapeutic Agent for Chronic Sinusitis
MXPA06014648A (es) * 2004-06-28 2007-02-12 Alcon Inc Formulaciones topicas para tratar pacedimientos alergicos.
DK1814538T3 (da) * 2004-11-24 2009-11-02 Alcon Inc Fremgangsmåde til administration af næsespray
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
WO2007007863A1 (en) 2005-07-08 2007-01-18 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
TWI409081B (zh) 2006-11-09 2013-09-21 Alcon Res Ltd 用於藥物輸送之水不溶性聚合物基質
BRPI0720431A2 (pt) * 2006-12-18 2013-12-31 Alcon Res Ltd Dispositivos e métodos para a distribuição de fármaco oftálmico
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
WO2008097220A1 (en) * 2007-02-07 2008-08-14 Alcon, Inc. Olopatadine formulations for topical nasal administration
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
BRPI0912985A2 (pt) * 2008-05-19 2015-10-13 Alcon Res Ltd composições farmacêuticas com polímero de carboxivinila e polímero de povidona
CN102089039B (zh) * 2008-08-26 2013-10-23 博磊科技股份有限公司 带静电荷口罩过滤产品和用于增加过滤效率的方法
KR20110056526A (ko) * 2008-08-28 2011-05-30 트루텍 코프. 항히스타민 및 유사-항히스타민 코 외용약, 생성물 및 방법
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
AU2010273347B2 (en) * 2009-07-17 2015-04-30 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
WO2011027322A1 (en) * 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
RU2557290C2 (ru) * 2009-09-25 2015-07-20 Шайр Орфан Терапис ГмбХ Новые агонисты npr-b
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
US20120264681A1 (en) * 2010-11-08 2012-10-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
MA47418A (fr) 2017-02-01 2021-06-02 Takeda Pharmaceuticals Co Composés et compositions pour le traitement de troubles ophtalmiques
JP7037349B2 (ja) * 2017-06-23 2022-03-16 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
WO2018235935A1 (ja) * 2017-06-23 2018-12-27 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
JPWO2021112240A1 (enExample) * 2019-12-06 2021-06-10
TWI896607B (zh) * 2020-03-31 2025-09-11 日商參天製藥股份有限公司 填充於樹脂製容器之含銀鹽眼科用水性組合物
CN111700860A (zh) * 2020-07-09 2020-09-25 浙江尖峰药业有限公司 盐酸奥洛他定滴眼液及其制备方法
CN119318630B (zh) * 2024-10-16 2025-08-22 苏州欧康维视生物科技有限公司 一种阿托品药物组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
ES2053678T3 (es) * 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
JP3662944B2 (ja) 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
WO1998056381A1 (en) * 1997-06-09 1998-12-17 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
DK1037627T3 (da) 1998-07-14 2001-10-01 Alcon Lab Inc Anvendelse af 11-(3-dimethylamino-propyliden)-6, 11-dihydrodibenz[b,e]oxepin-2-eddikesyre og af farmaceutisk acceptable salte deraf til fremstillingen af et lægemiddel til behandlingen af non-allergiske...
US6146622A (en) 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
AU753462B2 (en) * 1998-10-27 2002-10-17 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174914B1 (en) * 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
AU7363700A (en) 1999-09-21 2001-04-24 Alcon Laboratories, Inc. Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions
US6649602B1 (en) 1999-11-18 2003-11-18 Alcon, Inc. Use of an H1 antagonist and a safe steroid to treat eye conditions
ATE291913T1 (de) 2000-01-25 2005-04-15 Alcon Inc Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
BR0316203A (pt) 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica

Also Published As

Publication number Publication date
US20030055102A1 (en) 2003-03-20
JP2013127005A (ja) 2013-06-27
DK1399127T3 (da) 2005-06-13
CN1525849A (zh) 2004-09-01
WO2003002093A1 (en) 2003-01-09
JP5328947B2 (ja) 2013-10-30
JP2010150292A (ja) 2010-07-08
BR0210707A (pt) 2004-07-20
JP2012107046A (ja) 2012-06-07
CA2447924C (en) 2009-11-03
JP2009114213A (ja) 2009-05-28
EP1399127B1 (en) 2005-05-11
BRPI0210707B1 (pt) 2015-08-04
PT1399127E (pt) 2005-07-29
KR20040025919A (ko) 2004-03-26
MXPA03011947A (es) 2004-03-26
PL367780A1 (en) 2005-03-07
ATE295149T1 (de) 2005-05-15
US7402609B2 (en) 2008-07-22
US6995186B2 (en) 2006-02-07
AR034619A1 (es) 2004-03-03
AU2002310461B2 (en) 2006-05-18
EP1399127A1 (en) 2004-03-24
CA2447924A1 (en) 2003-01-09
GC0000397A (en) 2007-03-31
DE60204142T2 (de) 2005-10-06
ZA200308771B (en) 2005-01-26
ES2238574T3 (es) 2005-09-01
TWI231759B (en) 2005-05-01
US20050158387A1 (en) 2005-07-21
PL205565B1 (pl) 2010-05-31
JP2004536096A (ja) 2004-12-02
DE60204142D1 (de) 2005-06-16
JP4827374B2 (ja) 2011-11-30
KR100884711B1 (ko) 2009-02-19
CN1211125C (zh) 2005-07-20
HK1059573A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
BR0210707A (pt) Formulações de olopatadina para administração tópica
ES2052784T3 (es) Procedimiento para la produccion de una composicion terapeutica administrable localmente para una enfermedad inflamatoria.
ES2949139T3 (es) Composición que elimina la congestión nasal y que tiene actividad antivírica
KR20220044558A (ko) 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도
NO20044699L (no) Vaginalpleiesammensetning
KR101820184B1 (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BR0113861A (pt) Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
BR0011799A (pt) Combinação de bactéria de ácido láctico e seu uso para a prevenção e/ou tratamento de infecções e condições inflamatórias
BR0207694A (pt) Composto ou um sal, solvato ou derivado fisiologicamente funcional deste, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, combinação, uso de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste farmaceuticamente aceitáveis, processo para a preparação de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste, e, intermediários
BRPI0416854B8 (pt) suspensão aquosa estéril de ciclesonida adequada para nebulização, método para sua preparação e uso da dita suspensão, bem como produto farmacêutico
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
JP2003206241A (ja) 眼科用剤
US9629847B2 (en) Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
BRPI0721255B8 (pt) composições de olopatadina para administração nasal tópica
BR0316132A (pt) Método para estimular o crescimento de cabelo utilizando benzopiranos
RU2018125252A (ru) Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции
CA2901208A1 (en) Topical ocular analgesic agents
RU2720993C2 (ru) Пирролидон-карбоновая кислота (рса) для офтальмологического применения
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
BRPI0411524A (pt) formulação farmacêutica de amoxicilina e clavulanato, uso de carboximetilcelulose de sódio, e, método de tratar infecção bacteriana em pacientes pediátricos
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2727 DE 11-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.